SCHEMBL2268507

SCHEMBL2268507

CC(C)(C)OC(=O)NC1([C@@H]2CCN(Cc3ccccc3)C2)CC1

nearest known ligand 0.48

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
NPFFR1 Q9GZQ6 5/20 0.48
NPFFR2 Q9Y5X5 5/20 0.48
KMT2A Q03164 3/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
DRD4 P21917 1/20 0.44
BCHE P06276 3/20 0.43
MEN1 O00255 2/20 0.43
KDM4E B2RXH2 1/20 0.43
ALDH1A1 P00352 1/20 0.43
RAB9A P51151 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
SCN4A P35499 2/20 0.43
MAOB P27338 1/20 0.43
ACHE P22303 1/20 0.42
MCHR1 Q99705 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5768492 1.00 NPFFR1 (0.48) NPFFR1NPFFR2KMT2AL3MBTL1DRD4
SCHEMBL4675629 0.96 KMT2A (0.47) NPFFR1NPFFR2KMT2AL3MBTL1DRD4
SCHEMBL5232335 0.90 KMT2A (0.44) NPFFR1NPFFR2KMT2AL3MBTL1DRD4
SCHEMBL5235530 0.90 KMT2A (0.44) NPFFR1NPFFR2KMT2AL3MBTL1DRD4
SCHEMBL7518231 0.87 NPFFR1 (0.48) NPFFR1NPFFR2KMT2AL3MBTL1BCHE
SCHEMBL14087066 0.87 NPFFR1 (0.50) NPFFR1NPFFR2KMT2AL3MBTL1BCHE
SCHEMBL34473649 0.85 KMT2A (0.47) NPFFR1NPFFR2KMT2AL3MBTL1BCHE
SCHEMBL16032495 0.84 KMT2A (0.47) NPFFR1NPFFR2KMT2AL3MBTL1BCHE
SCHEMBL16032497 0.84 KMT2A (0.47) NPFFR1NPFFR2KMT2AL3MBTL1BCHE
SCHEMBL16032494 0.84 KMT2A (0.47) NPFFR1NPFFR2KMT2AL3MBTL1BCHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1693364-B1 INTERMEDIATES FOR THE PRODUCTION OF OPTICALLY ACTIVE CYCLOPROPYLAMINE DERIVATIVES AND PROCESS FOR THE PRODUCTION OF THE INTERMEDIATES DAIICHI SANKYO CO LTD (JP) 2015-05-20 EP disclosed
US-7994344-B2 Intermediates for the production of optically active cyclopropylamine derivatives and process for the production of the intermediates DAIICHI SANKYO COMPANY, LIMITED (JP) 2011-08-09 US disclosed
US-20090240066-A1 INTERMEDIATES FOR THE PRODUCTION OF OPTICALLY ACTIVE CYCLOPROPYLAMINE DERIVATIVES AND PROCESS FOR THE PRODUCTION OF THE INTERMEDIATES DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2009-09-24 US disclosed
US-7569599-B2 Intermediates for the production of optically active cyclopropylamine derivatives and process for the production of the intermediates DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2009-08-04 US disclosed
US-20070117988-A1 Intermediates for the production of optically active cyclopropylamine derivatives and process for the production of the intermediates DAIICHI SANKYO COMPANY, LIMITED (JP) 2007-05-24 US disclosed
EP-1693364-A1 INTERMEDIATES FOR THE PRODUCTION OF OPTICALLY ACTIVE CYCLOPROPYLAMINE DERIVATIVES AND PROCESS FOR THE PRODUCTION OF THE INTERMEDIATES DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2006-08-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070117988-A1 Intermediates for the production of optically active cyclopropylamine derivatives and process for the production of the intermediates RAP1A, RHOA, MGMT NPFFR1 938/4885NPFFR2 1356/4885KMT2A 1498/4885
US-20090240066-A1 INTERMEDIATES FOR THE PRODUCTION OF OPTICALLY ACTIVE CYCLOPROPYLAMINE DERIVATIVES AND PROCESS FOR THE PRODUCTION OF THE INTERMEDIATES RAP1A, RHOA, MGMT NPFFR1 938/4885NPFFR2 1356/4885KMT2A 1498/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.